GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Femasys Inc (NAS:FEMY) » Definitions » Shares Outstanding (Diluted Average)

Femasys (Femasys) Shares Outstanding (Diluted Average) : 21.78 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Femasys Shares Outstanding (Diluted Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Femasys's average diluted shares outstanding for the quarter that ended in Mar. 2024 was 21.78 Mil.


Femasys Shares Outstanding (Diluted Average) Historical Data

The historical data trend for Femasys's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Femasys Shares Outstanding (Diluted Average) Chart

Femasys Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (Diluted Average)
9.06 9.11 6.71 11.82 15.38

Femasys Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shares Outstanding (Diluted Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.87 13.11 15.09 21.43 21.78

Femasys Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Femasys  (NAS:FEMY) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Femasys Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of Femasys's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Femasys (Femasys) Business Description

Industry
Traded in Other Exchanges
N/A
Address
3950 Johns Creek Court, Suite 100, Suwanee, GA, USA, 30024
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
Executives
Keith J Kendall director 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Alistair Milnes director C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Christine E Thomas officer: SVP, Regulatory & Clinical 2836 SW 117TH STREET, GAINESVILLE FL 32606
Dov Elefant officer: Chief Financial Officer EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Wendy Perrow director C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Edward Evantash officer: Chief Medical Officer 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
John Dyett director, 10 percent owner 11111 SANTA MONICA BLVD., SUITE 2250, LOS ANGELES CA 90025
Adams John Q Jr director 35 WYCK HILL LANE, WESTLAKE TX 76262
Edward R Uzialko director, 10 percent owner 4605 DUDLEY LANE, ATLANTA GA 30327
Charles Larsen director 28 SANDPIPER ROAD, TAMPA FL 33609
Kathy Lee-sepsick director, officer: Chief Executive Officer 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Daniel Scott Currie officer: Senior VP, Operations 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Kelley Hoskin Violet Alexandria officer: VP, Clinical & Medical Affairs 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Gary Thompson director 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
William Benson Witte director 11111 SANTA MONICA BLVD., SUITE 2250, LOS ANGELES CA 90025

Femasys (Femasys) Headlines

From GuruFocus